Cetrorelix pamoate in patients with symptomatic BPH [benign prostatic hyperplasia]: a double-blind, placebo-controlled efficacy study.

Trial Profile

Cetrorelix pamoate in patients with symptomatic BPH [benign prostatic hyperplasia]: a double-blind, placebo-controlled efficacy study.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2013

At a glance

  • Drugs Cetrorelix (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 21 Nov 2012 New source identified and integrated (German Clinical Trials Register record: DRKS00004141).
    • 14 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Dec 2009 All patients have been followed up to week 52; reported by AEterna Zentaris in a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top